Published in Oncogene on February 27, 2003
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 5.59
Mechanisms of human papillomavirus-induced oncogenesis. J Virol (2004) 3.95
Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev (2005) 1.97
Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics (2009) 1.45
Non-random integration of the HPV genome in cervical cancer. PLoS One (2012) 1.43
Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer (2005) 1.27
Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc Natl Acad Sci U S A (2004) 1.22
Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas. PLoS One (2013) 1.19
Human papillomavirus molecular biology and disease association. Rev Med Virol (2015) 1.09
Papillomavirus genomes associate with BRD4 to replicate at fragile sites in the host genome. PLoS Pathog (2014) 1.00
Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways. J Virol (2013) 0.96
Dr.VIS: a database of human disease-related viral integration sites. Nucleic Acids Res (2011) 0.95
The relationship between oral squamous cell carcinoma and human papillomavirus: a meta-analysis of a Chinese population (1994-2011). PLoS One (2012) 0.94
Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation. J Virol (2004) 0.93
Integration of HPV6 and downregulation of AKR1C3 expression mark malignant transformation in a patient with juvenile-onset laryngeal papillomatosis. PLoS One (2013) 0.91
Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology (2011) 0.91
NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome. Br J Cancer (2015) 0.91
Are common fragile sites merely structural domains or highly organized "functional" units susceptible to oncogenic stress? Cell Mol Life Sci (2014) 0.90
A TRF1-controlled common fragile site containing interstitial telomeric sequences. Chromosoma (2012) 0.89
The Role of the DNA Damage Response throughout the Papillomavirus Life Cycle. Viruses (2015) 0.89
Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour. Int J Exp Pathol (2006) 0.87
Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression. Am J Pathol (2004) 0.87
Regulation of the life cycle of HPVs by differentiation and the DNA damage response. Future Microbiol (2013) 0.87
Deregulation of the miRNAs expression in cervical cancer: human papillomavirus implications. Biomed Res Int (2013) 0.85
Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology. Oncotarget (2016) 0.85
HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu Rev Med (2015) 0.84
Emerging role of microRNA-21 in cancer. Biomed Rep (2016) 0.84
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Transcriptionally active regions are the preferred targets for chromosomal HPV integration in cervical carcinogenesis. PLoS One (2015) 0.82
Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers (Basel) (2014) 0.82
Modulation of the DNA damage response during the life cycle of human papillomaviruses. Virus Res (2016) 0.81
ATR preferentially interacts with common fragile site FRA3B and the binding requires its kinase activity in response to aphidicolin treatment. Mutat Res (2010) 0.81
HPVbase--a knowledgebase of viral integrations, methylation patterns and microRNAs aberrant expression: As potential biomarkers for Human papillomaviruses mediated carcinomas. Sci Rep (2015) 0.80
BIRC2 amplification in squamous cell carcinomas of the uterine cervix. Virchows Arch (2012) 0.80
Cell-type specific transcriptional activities among different papillomavirus long control regions and their regulation by E2. Virology (2009) 0.79
Multiple-integrations of HPV16 genome and altered transcription of viral oncogenes and cellular genes are associated with the development of cervical cancer. PLoS One (2014) 0.79
A novel approach to simultaneously scan genes at fragile sites. BMC Cancer (2006) 0.79
Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells. BMC Cancer (2016) 0.79
Influence of physiologic folate deficiency on human papillomavirus type 16 (HPV16)-harboring human keratinocytes in vitro and in vivo. J Biol Chem (2012) 0.79
Recent Insights into the Control of Human Papillomavirus (HPV) Genome Stability, Loss, and Degradation. J Clin Med (2015) 0.79
IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep (2014) 0.78
Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry. J Virol (2012) 0.78
Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia. J Clin Microbiol (2011) 0.77
Prognostic significance of decreased expression of six large common fragile site genes in oropharyngeal squamous cell carcinomas. Transl Oncol (2014) 0.77
The role of fragile sites in sporadic papillary thyroid carcinoma. J Thyroid Res (2012) 0.77
MicroRNA miR-16-1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells. Int J Clin Exp Med (2015) 0.76
Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer. Infect Agent Cancer (2016) 0.75
Meta-Analysis of DNA Tumor-Viral Integration Site Selection Indicates a Role for Repeats, Gene Expression and Epigenetics. Cancers (Basel) (2015) 0.75
Association between folate status and cervical intraepithelial neoplasia. Eur J Clin Nutr (2016) 0.75
MicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2. J Cancer (2016) 0.75
Mate-Pair Sequencing as a Powerful Clinical Tool for the Characterization of Cancers with a DNA Viral Etiology. Viruses (2015) 0.75
Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer (2016) 0.75
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
Chromosomal radiosensitivity of human immunodeficiency virus positive/negative cervical cancer patients in South Africa. Mol Med Rep (2015) 0.75
The "enemies within": regions of the genome that are inherently difficult to replicate. F1000Res (2017) 0.75
DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer. Oncotarget (2017) 0.75
Microbial Signatures Associated with Oropharyngeal and Oral Squamous Cell Carcinomas. Sci Rep (2017) 0.75
Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene (2002) 5.40
Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol (2008) 3.94
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol (2012) 2.70
A role for common fragile site induction in amplification of human oncogenes. Cancer Cell (2002) 2.63
The learning curve of robotic hysterectomy. Obstet Gynecol (2013) 2.47
Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene (2003) 2.44
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 2.40
Premature menopause or early menopause: long-term health consequences. Maturitas (2009) 2.33
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int (2008) 2.26
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol (2006) 2.18
Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene (2002) 2.16
3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics (2009) 2.12
Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol (2003) 2.11
Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet (2007) 2.00
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology (2004) 1.95
Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause (2008) 1.92
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients. J Vasc Interv Radiol (2011) 1.85
Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One (2010) 1.85
HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene (2004) 1.82
Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer (2009) 1.68
AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer (2005) 1.58
Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res (2002) 1.57
Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res (2004) 1.56
MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci (2003) 1.54
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc (2010) 1.51
A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene (2004) 1.47
Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril (2008) 1.42
FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq. Bioinformatics (2011) 1.41
High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology (2008) 1.34
Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res (2003) 1.33
Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer (2006) 1.32
Human TopBP1 ensures genome integrity during normal S phase. Mol Cell Biol (2005) 1.31
Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res (2002) 1.29
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene (2005) 1.24
Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol (2005) 1.24
The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer (2002) 1.22
LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol (2011) 1.21
Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer (2003) 1.21
Identification of long stress-induced non-coding transcripts that have altered expression in cancer. Genomics (2010) 1.17
Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med (2007) 1.17
Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond Engl) (2009) 1.16
Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene (2003) 1.13
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res (2003) 1.12
Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene (2005) 1.12
Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet (2010) 1.10
Noninvasive treatment of uterine fibroids: early Mayo Clinic experience with magnetic resonance imaging-guided focused ultrasound. Mayo Clin Proc (2006) 1.08
Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol (2004) 1.06
Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle (2012) 1.06
Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer (2004) 1.05
Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg (2009) 1.03
Evidence that instability within the FRA3B region extends four megabases. Oncogene (2002) 0.98
The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet (2005) 0.96
Psychological distress (depression and anxiety) in people with head and neck cancers. Med J Aust (2010) 0.96
Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol (2007) 0.96
Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol (2007) 0.96
Very large common fragile site genes and their potential role in cancer development. Cell Mol Life Sci (2014) 0.96
Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res (2007) 0.95
Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination. PLoS One (2013) 0.95
Validation of referral guidelines for women with pelvic masses. Obstet Gynecol (2005) 0.95
Transcriptional profiling by sequencing of oropharyngeal cancer. Mayo Clin Proc (2012) 0.94
Human papillomavirus-associated oropharyngeal squamous cell carcinomas: primary tumor burden and survival in surgical patients. Ann Otol Rhinol Laryngol (2009) 0.94
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene (2003) 0.94
Host genetic polymorphism analysis in cervical cancer. Clin Chem (2002) 0.93
Relationship between FRA11F and 11q13 gene amplification in oral cancer. Genes Chromosomes Cancer (2007) 0.93
Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Int J Gynecol Pathol (2012) 0.92
Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol (2004) 0.91
Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma. Gynecol Oncol (2012) 0.90
Next-generation sequencing: a transformative tool for vaccinology. Expert Rev Vaccines (2009) 0.88
Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol (2008) 0.88
Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol (2006) 0.88
Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol (2008) 0.87
Understanding cellular leiomyomas: a case-control study. Am J Obstet Gynecol (2010) 0.87
Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol (2006) 0.87
Magnetic resonance elastography of uterine leiomyomas: a feasibility study. Fertil Steril (2010) 0.87
Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog Brain Res (2004) 0.86
Prevention, diagnosis, and treatment of cervical cancer. Mayo Clin Proc (2007) 0.86
The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancer. Gynecol Oncol (2011) 0.86
Positioning of cervical carcinoma and Burkitt lymphoma translocation breakpoints with respect to the human papillomavirus integration cluster in FRA8C at 8q24.13. Cancer Genet Cytogenet (2004) 0.86
Disabled-1 is a large common fragile site gene, inactivated in multiple cancers. Genes Chromosomes Cancer (2008) 0.84
A selected group of large common fragile site genes have decreased expression in oropharyngeal squamous cell carcinomas. Genes Chromosomes Cancer (2014) 0.84
Screening for cervical cancer and initial treatment of patients with abnormal results from papanicolaou testing. Mayo Clin Proc (2005) 0.83
Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol (2005) 0.83
Efficacy of thermal balloon ablation in patients with abnormal uterine bleeding. Am J Obstet Gynecol (2003) 0.83
Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol (2011) 0.82
Consensus-degenerate hybrid oligonucleotide primers (CODEHOP) for the detection of novel papillomaviruses and their application to esophageal and tonsillar carcinomas. J Virol Methods (2005) 0.82
Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol (2006) 0.82
Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. Am J Hematol (2013) 0.81
Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg (2006) 0.80
Assembly intermediates in polyketide biosynthesis: enantioselective syntheses of beta-hydroxycarbonyl compounds. Org Biomol Chem (2005) 0.80